A randomized phase II trial of docetaxel or pemetrexed with or without gefitinib in elderly advanced non-small cell lung cancer patients harboring activating EGFR mutation after failure of the therapy as first-line treatment.
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2013
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Apr 2012 New trial record